Business Context and Reporting Period
This Form 8-K Current Report from Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) covers events occurring on September 8, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes regarding director elections, auditor ratification, and amendments to the equity incentive plan.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance data.
Material Changes and Voting Results
As of the record date (July 20, 2026), 48,885,777 shares of common stock were outstanding and entitled to vote. The following material actions were approved by stockholders:
- Director Elections: Stockholders elected Brian Daniels, M.D., and Laura Stoppel, Ph.D., as Class II directors for three-year terms.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Equity Plan Amendment: Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase the authorized share reserve by 5,097,095 shares. The amendment also includes shares issuable upon the exercise of pre-funded warrants in the calculation of the annual automatic share reserve increase.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. The document references the definitive proxy statement filed on August 3, 2026, for a detailed summary of the Amended 2024 Plan features.
Investor Verification Checklist
- Verify the final share count and voting percentages for the amendment to the 2024 Equity Incentive Plan (Proposal 3) to assess potential dilution impact.
- Review the full text of the Amended 2024 Plan (Exhibit 10.1) to understand the specific terms of the increased share reserve and pre-funded warrant inclusion.
- Confirm the tenure of the newly elected Class II directors (Brian Daniels and Laura Stoppel) through the 2029 annual meeting.
- Check the 2026 Proxy Statement for additional context on the rationale behind the equity plan amendment.